TEVA.N Teva Pharmaceutical Industries Limited Sponsored ADR

January 5 Deadline Alert: Law Offices of Howard G. Smith Reminds Teva Pharmaceutical Industries Limited Investors of Upcoming Lead Plaintiff Deadline and Encourages Investors to Contact the Firm

Law Offices of Howard G. Smith reminds investors of the upcoming January 5, 2017 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Teva Pharmaceutical Industries Limited (“Teva” or the “Company”) (NYSE: TEVA) securities between February 10, 2014 and November 3, 2016, inclusive (the “Class Period”). Teva investors have until January 5, 2017 to file a lead plaintiff motion.

On November 3, 2016, Bloomberg published the article “U.S. Charges in Generic-Drug Probe to Be Filed by Year End” which discussed the Department of Justice’s two year investigation of suspected price collusion by several pharmaceutical companies, including Teva, which will likely result in prosecutors filing criminal charges by the end of the year.

The complaint filed in this lawsuit alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (1) Teva and several of its pharmaceutical industry peers colluded to fix generic drug prices; (2) the foregoing conduct constituted a violation of federal antitrust laws; (3) consequently, Teva’s revenues during the Class Period were in part the result of illegal conduct; and (4) as a result, Teva’s public statements were materially false and misleading at all relevant times.

If you purchased Teva shares, you may move the Court no later than January 5, 2017 to request appointment as lead plaintiff. To be a member of the class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to [email protected], or visit our website at http://www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

EN
30/12/2016

Underlying

Reports on Teva Pharmaceutical Industries Limited Sponsored ADR

 PRESS RELEASE

U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Applic...

U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults Olanzapine long-acting injectable (LAI) suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation1If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations1Teva is committed to advancing this innovative treat...

 PRESS RELEASE

Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated cli...

Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD patients who had responded after 14 weeks of inductionDuvakitug was well tolerated and safety was consistent with the induction studyFindings reinforce the potential of duvakitug which is in ongoing phase 3 programs in UC and CD Teva will hold an investor call and live webcast today, Tuesday, February 17, 2026, at 8:00 a.m. ...

Si Yong Ng
  • Si Yong Ng

Lucror Analytics - Convertibles Brief

In today's Convertibles Brief publication we comment on developments of the following high yield issuers: Teva

Haidje Rustau ... (+5)
  • Haidje Rustau
  • Jayanth Kandalam
  • Peter Low
  • Si Yong Ng
  • Tanvi Arora

Lucror Analytics - Morning Views Europe

In today's Morning Views publication we comment on developments of the following high yield issuers: Virgin Media O2, Italmatch Chemicals, Trivium, Air Baltic, Travelodge, Teva

 PRESS RELEASE

Teva Innovative Portfolio and Consistent Execution of Pivot to Growth ...

Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential Teva delivers 3 consecutive years of growth - 2025 revenues of $17.3 billion, an increase of 4% year-over-year (YoY) in U.S. dollars, or 3% in local currency (LC) terms, compared to 2024. Excluding Japan BV, revenues increased 5% YoY in LC.Key Innovative brands continued to drive growth and provide value for patients, with 2025 revenues surpassing $3 billion, +35% YoY in LC: AUSTEDO® global revenues of $2.26 bill...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch